摘要
目的 :探讨前列腺素E1治疗重型病毒性肝炎的临床疗效。方法 :6 0例重型病毒性肝炎患者随机分成治疗组 30例对照组 30例 ,对照组给予常规护肝 ,退黄及对症治疗 ,治疗组在给予常规对症治疗基础上 ,加用前列腺素E1(PGE1)静滴。观察疗效和不良反应。结果 :治疗组有效率为 76 .6 7% ,对照组为 4 6 .6 7%。治疗组胆红素降低明显优于对照组 ,肝肾综合症发生率明显低于对照组 (P <0 .0 5 ) ,不良反应轻微。结论
Objective: To investigate the therapeutic effect of prostagladin E 1 (PGE 1) on severe viral hepatitis.Methods: 60 severe viral hepatitis patients were divided into a treated group and a controlled group, each group consisted of 30 cases. The patients in the treated group received a combined routine therapy with venous infusion of prostaglandin E 1 (PGE 1), the patients in the contralled group received a routine therapy only.Result: The rate of cure and improvement in the treated group was 76.67% , that in the controlled group was 46.67% ( P < 0.05 ), The decrease of the total serum bilirubin in the treated group was more significant than the controlled group( P < 0.05 ), the incidence of hepatorenal syndrome in the treated group was less than the controlled group( P < 0.05 ). The side effects of prostaglandin E 1 were mild and could be tolerable.Conclusion: There is a marked difference between the groups. Prostaglandin E 1 is an effective and safe drug in the treatment of severe viral hepatitis.
出处
《中国药师》
CAS
2004年第5期372-374,共3页
China Pharmacist